Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 7/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22241839 | 0.82 | POLB (0.42) | PRMT5GPR119CYP19A1CYP11B2 | |
| SCHEMBL29310617 | 0.82 | PRMT5 (0.43) | PRMT5GPR119NOX4CYP19A1CYP11B2 | |
| SCHEMBL15742146 | 0.79 | CDC7 (0.51) | DGAT1CYP19A1CYP11B2 | |
| SCHEMBL30109054 | 0.79 | CYP11B2 (0.53) | CYP19A1CYP11B2CYP11B1 | |
| SCHEMBL6658922 | 0.75 | CYP17A1 (0.41) | DGAT1CYP19A1CYP11B2CYP11B1 | |
| SCHEMBL29311895 | 0.72 | CCR6 (0.41) | — | |
| SCHEMBL1044182 | 0.71 | ELANE (0.45) | PRMT5ELANE | |
| SCHEMBL8337902 | 0.70 | CYP2A6 (0.49) | ELANECYP19A1 | |
| SCHEMBL21463653 | 0.70 | LRRK2 (0.45) | — | |
| SCHEMBL30615479 | 0.70 | LRRK2 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | MCHR1 2034/4885PRMT5 3713/4885ELANE 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.